Aclaris Therapeutics, Inc.ACRSNASDAQ

Overview Intelligence Charts News Fundamentals Key Metrics Earnings Growth Financials Insiders

Latest News

globenewswire.com

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

- Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD).

defenseworld.net

Aclaris Therapeutics Highlights Atopic Dermatitis Data Catalysts, ITK Progress at Leerink Conference

Aclaris Therapeutics (NASDAQ: ACRS) outlined multiple clinical and near-term development milestones across its large-molecule and small-molecule pipeline during a presentation at the Leerink Partners Global Healthcare Conference, with management emphasizing upcoming data readouts in atopic dermatitis and progress in its ITK inhibitor franchise. Pipeline overview and near-term milestones Chairman and CEO Neal Walker described Aclaris as

zacks.com

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.1 per share a year ago.

globenewswire.com

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model - WAYNE, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year ended 2025 and provided a corporate update.

globenewswire.com

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Patients with Asthma with its Novel Bispecific Anti-TSLP/IL-4Rα Antibody ATI-052

WAYNE, Pa., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial of ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody, in asthma. This announcement follows the recent initiation of the Company's Phase 1b POC trial of ATI-052 in atopic dermatitis (AD).

247wallst.com

Here Are Friday’s Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More

Pre-Market Stock Futures: Futures are trading lower as we prepare to close out the trading week. What a difference a day can make. After a blockbuster rally on Wednesday, the stock market reversed course and sold off on Thursday, and that could carry over into today. While the major indices ended off their midday lows,... Here Are Friday's Top Wall Street Analyst Research Calls: Broadcom, Circle Internet, Kenvue, Medtronic, Sandisk, Southwest Airlines, Spotify, and More.

globenewswire.com

Aclaris Therapeutics' Novel ITK/JAK3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (AA)

globenewswire.com

Aclaris Therapeutics Initiates Phase 1b Proof-of-Concept Trial in Atopic Dermatitis (AD) with Its Novel Bispecific Antibody ATI-052

WAYNE, Pa., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1b proof-of-concept (POC) trial in atopic dermatitis (AD) for ATI-052, the Company's potential best-in-class investigational bispecific anti-TSLP/IL-4Rα antibody. “We are experiencing strong momentum in the ATI-052 clinical development program including the recent positive Phase 1a interim results which demonstrated a strong safety and tolerability profile, extended pharmacokinetics, and concentration-dependent pharmacodynamics even at the lowest dose,” said Dr. Jesse Hall, Chief Medical Officer of Aclaris.

defenseworld.net

Aclaris Therapeutics Reports Positive Interim Phase 1a ATI-052 Data, Speeds Up Development Plans

Aclaris Therapeutics (NASDAQ: ACRS) hosted an investor conference call on January 6, 2026 to discuss positive interim results from its ongoing first-in-human Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of ATI-052, a bispecific antibody designed to bind both thymic stromal lymphopoietin (TSLP) and IL-4 receptor (IL-4R). Management said the interim data,

seekingalpha.com

Aclaris Therapeutics, Inc. (ACRS) Discusses Positive Interim Results From ATI-052 Phase 1a Trial and Potential Therapeutic Advantages Transcript

globenewswire.com

Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

- Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended Dosing of up to Every Three Months - - Initiation of Phase 1b Proof-of-Concept (POC) Trials in Atopic Dermatitis (AD) and Asthma Now Expected in First Quarter of 2026; Planning Underway for Advancement of ATI-052 into Phase 2b Trial in AD in the Second Half of 2026 - - Management to Host a Conference Call to Discuss Update Today at 8:00 AM EST - WAYNE, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced positive interim results from the first-in-human Phase 1a single (SAD) and multiple ascending dose (MAD) trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052.

globenewswire.com

Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

WAYNE, Pa., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced it has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), effective at the close of trading today, December 19, 2025. The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark.

defenseworld.net

Savara (NASDAQ:SVRA) & Aclaris Therapeutics (NASDAQ:ACRS) Head-To-Head Survey

Aclaris Therapeutics (NASDAQ: ACRS - Get Free Report) and Savara (NASDAQ: SVRA - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Profitability This table compares Aclaris Therapeutics and Savara's

globenewswire.com

Aclaris Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

WAYNE, Pa., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Aclaris' Chief Executive Officer and other members of Aclaris' senior leadership team will participate in a fireside chat during the Piper Sandler 37th Annual Healthcare Conference in New York City. The discussion will take place on Tuesday December 2, 2025 at 11:00 AM EST.

zacks.com

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.

globenewswire.com

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of Phase 2 Trial in an Additional Indication Expected in the First Half of 2026 - - Timelines Reiterated for Top Line Clinical Results from Ongoing Trials of Investigational Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) and Anti-TSLP/IL-4R Bispecific Antibody ATI-052 - - Initiation of Phase 1b Proof-of-Concept Trials of ATI-052 in Asthma and Atopic Dermatitis (AD) Expected in the First Half of 2026 - - Strong Cash Runway Expected to Fund Operations into the Second Half of 2028 - WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2025 and provided a corporate update.

globenewswire.com

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November. On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Guggenheim 2nd Annual Healthcare Conference in Boston, MA.

zacks.com

What Makes Aclaris Therapeutics (ACRS) a Strong Momentum Stock: Buy Now?

Does Aclaris Therapeutics (ACRS) have what it takes to be a top stock pick for momentum investors? Let's find out.

seekingalpha.com

Aclaris Therapeutics, Inc. - Special Call

Aclaris Therapeutics, Inc. - Special Call Company Participants William Roberts - Senior VP of Corporate Communications & Investor Relations Neal Walker - Co-Founder, CEO & Chairman Roland Kolbeck - Chief Scientific Officer Joseph Monahan - Founder, Chairman of the Board & Chief Scientific Officer Hugh M. Davis - President, COO & Director Jesse Hall - Chief Medical Officer Zuzana Diamant Michael Cameron Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Thomas Smith - Leerink Partners LLC, Research Division Jiale Song - Jefferies LLC, Research Division Charles Ndiaye - Stifel, Nicolaus & Company, Incorporated, Research Division Seamus Fernandez - Guggenheim Securities, LLC, Research Division Biren Amin - Piper Sandler & Co., Research Division Presentation William Roberts Senior VP of Corporate Communications & Investor Relations Good morning, everyone.

globenewswire.com

Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025

WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will host it's 2025 R&D Day in Midtown, New York on Tuesday, October 14, 2025 at 8:00 AM ET to discuss the Company's progress in addressing therapeutic gaps in immuno-inflammatory markets.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance